

**Freedom of Information Request**

**Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:**

• Adalimumab – Humira	18
• Adalimumab Biosimilar	72
• Apremilast - unable to quantify shared care but 2 supplied via hospital	
• Bimekizumab	0
• Brodalumab	1
• Certolizumab	1
• Dimethyl fumarate - Unable to quantify. Shared care but 0 supplied via hospital pharmacy	
• Etanercept - Enbrel	
• Etanercept Biosimilar	6
• Guselkumab	7
• Infliximab – Remicade	0
• Infliximab Biosimilar	3
• Ixekizumab	16
• Risankizumab	4
• Secukinumab	8
• Tildrakizumab	3
• Ustekinumab	45

**Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

• Adalimumab – Humira	19
• Adalimumab Biosimilar	254
• Filgotinib	0
• Golimumab	4
• Infliximab – Remicade	33
• Infliximab Biosimilar	143
• Ozanimod	0
• Tofacitinib	12
• Ustekinumab	97
• Vedolizumab	86